EyePoint (EYPT) Return on Capital Employed (2011 - 2026)
EyePoint (EYPT) posted Return on Capital Employed of 97.64% for Q1 2026, down 8.62% sequentially from 89.89% in Q4 2025, and down 5138.0% YoY from 1.94% in Q1 2025.
EyePoint (EYPT) Return on Capital Employed (2011 - 2026) Analysis & Trends
EyePoint has reported Return on Capital Employed for 16 years, with the latest figure at 97.64% in Q1 2026.
- Quarterly Return on Capital Employed fell 5138.0% year-over-year to 97.64% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 97.64% (down 5138.0% YoY) and the FY2025 annual result came in at 68.73%, down 2555.0% from the prior year.
- Return on Capital Employed declined to 97.64% in Q1 2026 per EYPT's latest filing, from 89.89% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 28.21% in Q1 2022 and troughed at 110.64% in Q2 2023.
- A 5-year average of 60.45% and a median of 46.95% in 2024 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2023 and 2024: Return on Capital Employed tumbled 7618 bps in 2023, then surged 7338 bps in 2024.
- Over 5 years, Return on Capital Employed stood at 60.06% in 2022, then jumped by 36 bps to 38.62% in 2023, then dropped by 22 bps to 46.95% in 2024, then plunged by 91 bps to 89.89% in 2025, then declined by 9 bps to 97.64% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 97.64%, 89.89%, and 88.63% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | EyePoint | 1.25 Bn | 1.07 Bn | 507,000.00 | -146.57% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -146.57% |
| Mar 31, 2026 | -97.64% |
| Dec 31, 2025 | -89.89% |
| Sep 30, 2025 | -88.63% |
| Jun 30, 2025 | -63.30% |
| Mar 31, 2025 | -46.26% |
| Dec 31, 2024 | -46.95% |
| Sep 30, 2024 | -44.34% |
| Jun 30, 2024 | -37.26% |
| Mar 31, 2024 | -31.05% |
| Dec 31, 2023 | -38.62% |
| Sep 30, 2023 | -98.55% |
| Jun 30, 2023 | -110.64% |
| Mar 31, 2023 | -73.38% |
| Dec 31, 2022 | -60.06% |
| Sep 30, 2022 | -38.37% |
| Jun 30, 2022 | -34.47% |
| Mar 31, 2022 | -28.21% |
| Dec 31, 2021 | -28.77% |
| Sep 30, 2021 | -32.53% |